Unknown

Dataset Information

0

Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1-OH-midazolam in morbidly obese and weight loss surgery patients.


ABSTRACT: This study aimed to describe the pharmacokinetics of midazolam and its cytochrome P450 3A (CYP3A) mediated metabolite 1-OH-midazolam in morbidly obese patients receiving oral and i.v. midazolam before (n?=?20) and one year after weight loss surgery (n?=?18), thereby providing insight into the influence of weight loss surgery on CYP3A activity in the gut wall and liver. In a semiphysiologically based pharmacokinetic (semi-PBPK) model in which different blood flow scenarios were evaluated, intrinsic hepatic clearance of midazolam (CLint,H) was 2 (95% CI 1.40-1.64) times higher compared to morbidly obese patients before surgery (P??0.05), with low values for both groups. The results of the semi-PBPK model suggest that, in patients after weight loss surgery, CYP3A hepatic metabolizing capacity seems to recover compared to morbidly obese patients, whereas CYP3A mediated CLint,G was low for both populations and showed large interindividual variability.

SUBMITTER: Brill MJ 

PROVIDER: S-EPMC4728292 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1-OH-midazolam in morbidly obese and weight loss surgery patients.

Brill M J E MJ   Välitalo P A J PA   Darwich A S AS   van Ramshorst B B   van Dongen H P A HP   Rostami-Hodjegan A A   Danhof M M   Knibbe C A J CA  

CPT: pharmacometrics & systems pharmacology 20151218 1


This study aimed to describe the pharmacokinetics of midazolam and its cytochrome P450 3A (CYP3A) mediated metabolite 1-OH-midazolam in morbidly obese patients receiving oral and i.v. midazolam before (n = 20) and one year after weight loss surgery (n = 18), thereby providing insight into the influence of weight loss surgery on CYP3A activity in the gut wall and liver. In a semiphysiologically based pharmacokinetic (semi-PBPK) model in which different blood flow scenarios were evaluated, intrins  ...[more]

Similar Datasets

| S-EPMC4628089 | biostudies-literature
| S-EPMC7652802 | biostudies-literature
| S-EPMC5904241 | biostudies-literature
| S-EPMC3717871 | biostudies-literature
2007-10-26 | E-GEOD-5109 | biostudies-arrayexpress
| S-EPMC6585933 | biostudies-literature
| S-EPMC4906643 | biostudies-literature
| S-EPMC8572633 | biostudies-literature
| S-EPMC4171595 | biostudies-literature
| S-EPMC7694407 | biostudies-literature